+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Collaboration and Licensing Deals 2019-2023

  • PDF Icon

    Report

  • 1600 Pages
  • October 2023
  • Region: Global
  • CurrentPartnering
  • ID: 2067195
Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of oncology deals from 2019 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse oncology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

  • Trends in oncology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of oncology deal records covering pharmaceutical and biotechnology
  • The leading oncology deals by value
  • Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 - Financial deal terms for oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading oncology deals and dealmakers
4.1. Introduction
4.2. Most active in oncology partnering
4.3. List of most active dealmakers in oncology
4.4. Top oncology deals by value
Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by oncology therapeutic target
Deal directory
Deal directory - Oncology deals by company A-Z 2019 to 2023
Deal directory - Oncology deals by technology type 2019 to 2023
Deal type definitions
Table of figures
Figure 1: Oncology partnering since 2019
Figure 2: Oncology partnering by deal type since 2019
Figure 3: Oncology partnering by industry sector since 2019
Figure 4: Oncology partnering by stage of development since 2019
Figure 5: Oncology partnering by technology type since 2019
Figure 6: Oncology partnering by indication since 2019
Figure 7: Oncology deals with a headline value
Figure 8: Oncology deals with upfront payment values
Figure 9: Oncology deals with milestone payment
Figure 10: Oncology deals with royalty rates
Figure 11: Active oncology dealmaking activity since 2019
Figure 12: Top oncology deals by value since 2019

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 1ST Biotherapeutics
  • 2bPrecise
  • 2cureX
  • 2seventy bio
  • 2X Oncology
  • 3B Pharmaceuticals
  • 3D Medicines
  • 3P Biopharmaceuticals
  • 3SBio
  • 4baseCare
  • 4C Biomed
  • 4D Path
  • 4D Pharma
  • 5AM Ventures
  • 7 Hills Pharma
  • 9 Meters Biopharma
  • 48Hour Discovery
  • 111
  • 1717 Life Science Ventures
  • A*STAR Bioinformatics Institute
  • A*STAR Singapore Immunology Network
  • A*STAR’ Institute of Molecular and Cell Biology
  • A-Alpha Bio
  • A2 Biotherapeutics
  • A2A Pharmaceuticals
  • Aadi Bioscience
  • Aarvik Therapeutics
  • Abbisko Therapeutics
  • Abbvie
  • Abcam
  • AbCellera
  • Abcuro
  • Abdul Latif Jameel Health
  • Abexxa Biologics
  • Abilita Bio
  • Abingworth Management
  • Abintus Bio
  • Ablaze Pharmaceuticals
  • ABL Bio
  • Ab Magnitude Ventures
  • Abound Bio
  • Abpro
  • Abramson Cancer Center
  • AbSci
  • ABVC BioPharma
  • Abveris
  • ABX
  • Abzena
  • Academia Sinica
  • Academic and Community Cancer Research United
  • AC Bioscience
  • Accelerate Brain Cancer Cure
  • Accent Therapeutics
  • Accenture
  • Access to Comprehensive Genomic Profiling Coalition
  • Accord Healthcare
  • Accudata Systems
  • Accuray
  • ACEA Biosciences
  • ACEA Therapeutics
  • Acentrus Specialty
  • Acepodia
  • Acerand Therapeutics
  • Acerta Pharma
  • Aceso Life Science
  • Achilles Therapeutics
  • Acibadem University
  • Acino Pharma
  • Acoustic MedSystems
  • Acrivon Therapeutics
  • Acrotech Biopharma
  • Actelion
  • ACT Genomics
  • Actimed Therapeutics
  • Actinium Pharmaceuticals
  • Actuate Therapeutics
  • Actym Therapeutics
  • Acucela
  • Acuitas Therapeutics
  • Acuity Pharmaceuticals
  • Acupath Laboratories
  • Adagene
  • AdAlta
  • Adamis Pharmaceuticals
  • Adaptate Biotherapeutics
  • Adaptiiv
  • Adaptimmune
  • Adaptive Biotechnologies
  • AdaptVac
  • ADC Therapeutics
  • Addario Lung Cancer Medical Institute
  • Adgero Biopharmaceuticals
  • Adicet Bio
  • ADIENNE Pharma & Biotech
  • Adimab
  • Adium Pharma
  • Adlai Nortye
  • AdoRx Therapeutics
  • ADT Pharmaceuticals
  • Adult Brain Tumor Consortium
  • Aduro BioTech
  • Advaite
  • AdvaMed
  • Advanced Accelerator Applications
  • Advanced BioScience Laboratories
  • Advanced Dermatology and Cosmetic Surgery Group
  • Advanced Nuclear Medicine Ingredients
  • Advanced Proteome Therapeutics
  • Advanced Radiation Therapy
  • Advanz Pharma
  • Advaxis
  • Aeglea BioTherapeutics
  • Aerpio Pharmaceuticals
  • Aethlon Medical
  • Aetion
  • Aetna
  • AffaMed Therapeutics
  • Affigen
  • Affimed Therapeutics
  • Affinia Therapeutics
  • Again Life Italia
  • Agalimmune
  • AGC Biologics
  • Agena Bioscience
  • Agencja Badan Medycznych
  • Agendia
  • Agenus Bio
  • AgeX Therapeutics
  • Agilent Technologies
  • Agilvax
  • Agios Pharmaceuticals
  • AG Mednet
  • AgonOx
  • AiCure
  • Aidence
  • Aidoc
  • Aiforia Technologies
  • AIkido Pharma
  • Aileron Therapeutics
  • AimedBio
  • AIMM Therapeutics
  • Aion Therapeutic
  • AirXpanders
  • Ajax Therapeutics
  • Ajinomoto
  • Akeso Biopharma
  • Akoya Biosciences
  • Akrevia Therapeutics
  • AKSO Biopharmaceutical
  • Albany Medical College
  • Albert Einstein College of Medicine
  • Alcami
  • Alcedis
  • Alchemab
  • Aldevron
  • Alector
  • Aleta Biotherapeutics
  • Alex’s Lemonade Stand Foundation
  • Alibaba Health
  • Alkermes

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...